EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
+8.41%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$5.55B
AUM Growth
+$502M
(+9.9%)
Cap. Flow
+$203M
Cap. Flow
% of AUM
3.66%
Top 10 Holdings %
Top 10 Hldgs %
19.68%
Holding
934
New
51
Increased
198
Reduced
144
Closed
33
Top Buys
| 1 |
Cintas
CTAS
|
+$23.7M |
| 2 |
Sunrun
RUN
|
+$18.3M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$14.6M |
| 4 |
NOVA
Sunnova Energy
NOVA
|
+$14M |
| 5 |
Home Depot
HD
|
+$13.5M |
Top Sells
| 1 |
Silicon Motion
SIMO
|
+$25.9M |
| 2 |
NVIDIA
NVDA
|
+$25.7M |
| 3 |
Visa
V
|
+$16.9M |
| 4 |
Comcast
CMCSA
|
+$16.5M |
| 5 |
TJX Companies
TJX
|
+$14.5M |
Sector Composition
| 1 | Technology | 31.13% |
| 2 | Healthcare | 18.95% |
| 3 | Consumer Discretionary | 13.96% |
| 4 | Financials | 9.3% |
| 5 | Industrials | 7.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Intercontinental Exchange
ICE
$99.5B
| $798K | 0.01% |
5,837
-305
| -5% | -$41.7K |
|
377
Hershey
HSY
$38B
| $794K | 0.01% |
4,156
+115
| +3% | +$22K |
|
378
Citigroup
C
$176B
| $759K | 0.01% |
12,533
+2,703
| +27% | +$164K |
|
|
SWTX
379
DELISTED
SpringWorks Therapeutics
SWTX
| $749K | 0.01% |
12,300
| – | – |
|
380
GE Aerospace
GE
$293B
| $735K | 0.01% |
12,454
+673
| +6% | +$39.7K |
|
381
Cheniere Energy
LNG
$51.3B
| $724K | 0.01% |
7,000
-2,300
| -25% | -$238K |
|
382
Hamilton Lane
HLNE
$6.41B
| $716K | 0.01% |
6,857
+250
| +4% | +$26.1K |
|
383
Revvity
RVTY
$10B
| $703K | 0.01% |
3,600
| – | – |
|
384
Ligand Pharmaceuticals
LGND
$3.23B
| $700K | 0.01% |
6,893
| – | – |
|
385
Relay Therapeutics
RLAY
$700M
| $697K | 0.01% |
23,100
| – | – |
|
386
PNC Financial Services
PNC
$80.2B
| $691K | 0.01% |
+3,433
| New | +$691K |
|
387
Zai Lab
ZLAB
$3.49B
| $690K | 0.01% |
10,900
| – | – |
|
388
Celanese
CE
$5.09B
| $685K | 0.01% |
4,100
+1,000
| +32% | +$167K |
|
389
Hartford Financial Services
HIG
$36.7B
| $675K | 0.01% |
9,700
-2,100
| -18% | -$146K |
|
390
Aurinia Pharmaceuticals
AUPH
$1.62B
| $675K | 0.01% |
30,000
| – | – |
|
391
Beam Therapeutics
BEAM
$2.02B
| $672K | 0.01% |
8,500
-6,500
| -43% | -$514K |
|
392
Nektar Therapeutics
NKTR
$843M
| $665K | 0.01% |
3,120
| – | – |
|
393
Veracyte
VCYT
$2.55B
| $664K | 0.01% |
17,000
| – | – |
|
394
Fate Therapeutics
FATE
$111M
| $663K | 0.01% |
11,200
-6,000
| -35% | -$355K |
|
|
GAP
395
The Gap, Inc.
GAP
$8.96B
| $659K | 0.01% |
37,317
+15,900
| +74% | +$281K |
|
|
AMRN
396
Amarin Corp
AMRN
$317M
| $655K | 0.01% |
9,900
| – | – |
|
397
Kinder Morgan
KMI
$58.8B
| $646K | 0.01% |
40,800
-10,000
| -20% | -$158K |
|
398
Ocular Therapeutix
OCUL
$2.21B
| $632K | 0.01% |
95,800
| – | – |
|
399
Allogene Therapeutics
ALLO
$253M
| $626K | 0.01% |
40,800
| – | – |
|
400
Brown & Brown
BRO
$31.5B
| $621K | 0.01% |
8,900
| – | – |
|